Healthcare & Life Sciences Insights

Discover Latham’s latest insights into the commercial, regulatory, and legal developments shaping the global healthcare and life sciences landscape.

Latham’s cross-disciplinary team delivers insightful, practical guidance and sophisticated representation to a full spectrum of healthcare and life sciences companies across the globe, on every type of transaction or dispute a company may face.

Learn more about our capabilities

In the Spotlight

Healthcare & Life Sciences Market Update

Close up of Asian women with hi tech digital technology screen over the eye.

February 21, 2024 Webcast

2024 FDA Outlook: Healthcare & Life Sciences

Shiny transparent capsule filled with colorful spheres

January 25, 2024 Podcast

Episode 68 — Drug Pricing: Will Agencies Exercise March-In Rights Based on Drug Price?

January 4, 2024 Publication

2024 Drug Pricing Look Ahead: Federal, State Drug Pricing Plans Likely to Prompt Challenges

Drop of clear blue liquid from droper droping to test tube in laboratory with bright color blur background.

October 27, 2023 Client Alert

FDA to Address Proposed Rule to Subject Laboratory-Developed Tests to Agency Oversight in Public Webinar

March 15, 2024 Publication

Recent Updates on Emerging Trends in the Global Regulation of Digital Health

In the latest edition of ICLG Digital Health 2024, partners Eveline Van Keymeulen and Elizabeth Richards, counsel Nicole Liffrig Molife, and associate Oliver Mobasser discuss emerging trends in the global regulation of digital health in the US, EU, and UK, and the frameworks striving to catch up with technological advancement.

November 14, 2023 Publication

CPR Manual: Mitigating Risk in Life Sciences Transactions

Partner Judith Hasko contributes a chapter to the International Institute for Conflict Prevention and Resolution’s manual to aid legal practitioners with drafting life sciences transactions.

November 13, 2023 Publication

Clinical Trials: Overview (France)

November 8, 2023 Publication

Life Sciences Product Development Needs More Creative Fundraising

November 2, 2023 Client Alert

President Biden’s Executive Order on Artificial Intelligence — Initial Analysis of Private Sector Implications

March 06, 2024

Next Generation of Nicotine: Center for Tobacco Products — 2024 Outlook

Latham’s FDA Regulatory lawyers discuss CTP’s 2024 agenda for tobacco and nicotine products. MCLE credit offered.

February 21, 2024

2024 FDA Outlook: Healthcare & Life Sciences

Latham’s Healthcare & Life Sciences lawyers discuss FDA’s regulatory and legislative agenda for 2024. MCLE credit offered.

February 01, 2024

Episode 71 — Drug Pricing: A Look Ahead at Trends for 2024

Listen to this “lightning round” to hear how the policy and regulatory environment will likely remain hostile for pharmaceutical manufacturers, and how to address the turbulence that lies ahead.

January 25, 2024

Episode 68 — Drug Pricing: Will Agencies Exercise March-In Rights Based on Drug Price?

A new proposal seeks to reinvigorate the Bayh-Dole Act by allowing government to consider price as a factor when electing to exercise march-in rights.

December 13, 2023

Episode 62 — Has FDA Meaningfully Changed Its Restrictions on Off-Label Communications?

New draft guidance document signals an expanded safe harbor for communicating scientific information on unapproved uses of approved medical products.

Episode 61 Drug Pricing New OIG Guidance Reaffirms the Seven Elements of Effective Compliance

December 08, 2023

Episode 61 — Drug Pricing: New OIG Guidance Reaffirms the Seven Elements of an Effective Compliance Program

Hear from Latham attorneys and a leading industry practitioner what the OIG compliance guidance means for drug manufacturers.

December 05, 2023

Common Pitfalls in Structuring Non-Dilutive Financings Using Licenses or Collaborations

Latham Healthcare & Life Sciences partners discuss alternative financing through strategic licensing and partnerships as part of the Jefferies London Healthcare Conference.

October 20, 2023